ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,260.09
1.07%
Dow Jones
42,392.27
-0.36%
Gold vs US Dollar
2,661.845
0.13%
Brent Oil
76.04
0.24%
Bitcoin
96,941.23
0.05%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. AMEX
  6. Cel Sci Corporation New (CVM)

  7. Cel Sci Corporation New (CVM) News

Cel Sci (CVM)

Cel Sci Corporation New
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:CVM
DateTimeSourceHeadlineSymbolCompany
02/01/202519:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
02/01/202519:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
02/01/202519:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
31/12/202421:15Edgar (US Regulatory)Form 8-K - Current reportAMEX:CVMCel Sci Corporation New
31/12/202421:05Business WireCEL-SCI Announces Closing of $5 Million OfferingAMEX:CVMCel Sci Corporation New
30/12/202422:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:CVMCel Sci Corporation New
30/12/202421:16Edgar (US Regulatory)Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405AMEX:CVMCel Sci Corporation New
30/12/202401:41Business WireCEL-SCI Announces Pricing of $5 Million Public OfferingAMEX:CVMCel Sci Corporation New
27/12/202422:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:CVMCel Sci Corporation New
27/12/202422:05Business WireCEL-SCI Announces Proposed Public Offering of Common StockAMEX:CVMCel Sci Corporation New
12/12/202414:15Business WireCEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer StudyAMEX:CVMCel Sci Corporation New
15/11/202421:30Edgar (US Regulatory)Form 8-K - Current reportAMEX:CVMCel Sci Corporation New
13/11/202413:30Edgar (US Regulatory)Form 8-K - Current reportAMEX:CVMCel Sci Corporation New
08/11/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:CVMCel Sci Corporation New
07/11/202413:15Business WireU.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025AMEX:CVMCel Sci Corporation New
30/10/202421:21Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]AMEX:CVMCel Sci Corporation New
25/10/202421:17Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933AMEX:CVMCel Sci Corporation New
22/10/202413:15Business WireFDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer PatientsAMEX:CVMCel Sci Corporation New
11/10/202421:00Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementAMEX:CVMCel Sci Corporation New
10/10/202420:05Edgar (US Regulatory)Form AW - Amendment Withdrawal RequestAMEX:CVMCel Sci Corporation New
08/10/202421:13Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]AMEX:CVMCel Sci Corporation New
01/10/202413:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
01/10/202413:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
01/10/202412:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
01/10/202410:00Business WireCEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck CancerAMEX:CVMCel Sci Corporation New
16/09/202411:30Business WireCEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and RadiationAMEX:CVMCel Sci Corporation New
10/09/202413:32Business WireCEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 CongressAMEX:CVMCel Sci Corporation New
04/09/202413:00Business WireThe UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing ClearanceAMEX:CVMCel Sci Corporation New
30/08/202420:32Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansAMEX:CVMCel Sci Corporation New
15/08/202412:00Business WireCEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial ResultsAMEX:CVMCel Sci Corporation New
 Showing the most relevant articles for your search:AMEX:CVM

Your Recent History

LSE
ARCM
Arc Minerals
LSE
BOD
Botswana Diamonds
LSE
SRES
Sunrise Resources
LSE
JLP
Jubilee Metals
LSE
SRT
Srt Marine Systems
LSE
BOO
Boohoo
LSE
PRTC
Puretech Health
LSE
MILA
Mila Resources
LSE
PTAL
Petrotal
LSE
FGEN
Foresight Environmental ...
LSE
MIRI
Mirriad Advertising
LSE
ATM
Andrada Mining
LSE
CPX
Cap-xx
LSE
AEP
Anglo-eastern Plantations
LSE
GRL
Goldstone Resources
LSE
GBP
Global Petroleum
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2025 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads